cortex with the highest-dose regimen. No significant change occurred with lower doses of methamphetamine, or in any other brain region tested. A reduction in BDNF levels in the serum was also observed with the highest concentration, but not with lower doses. Collectively, this data highlights the importance of the frontal cortex in methamphetamineinduced effects, and also the similar dose-response effect of methamphetamine on dopamine and BDNF expression.
moted by methamphetamine stimulates the reward circuitry, producing the psychoactive effects.
Dopamine depletion follows the period of heightened dopamine release. Although basal dopamine levels and presynaptic dopaminergic function recover gradually over time [4] , high levels and repeated exposure to methamphetamine can cause long-term damage to monoaminergic neurons, particularly at the dopaminergic nerve terminals [5] . A persistent decrease in dopamine transporter level is commonly used as an indicator of neurotoxicity. In monkeys, it was found that methamphetamine reduced the synaptosomal uptake of neurotransmitters in dopaminergic and serotonergic terminals that was shown to persist for up to 4 years [6] . Methamphetamine users have significantly reduced dopamine transporter density in the striatum which persists after recovery from drug abuse [7, 8] , although there is evidence that levels can gradually recover with protracted abstinence [9] .
Neurotrophins are endogenous proteins that exert a range of effects on the developing and mature central and peripheral nervous systems [10] . Survival signals emanating from neurotrophins are mediated by tropomyosin receptor kinase (trk) receptors [11] whereas the p75 neurotrophin receptor (p75NTR) mediates mainly apoptotic signals in response to pro-neurotrophins [12] . Neurotrophins are known to promote neuronal growth and survival during development, and to convey neuroprotection against the effects of toxic agents [10] . Brain-derived neurotrophic factor (BDNF) is the most commonly occurring neurotrophin [13] . BDNF has been shown to enhance the development of dopamine neurons in the substantia nigra, to increase the survival of mesencephalic cells [14] , and to protect against toxicity, including that produced by drugs of abuse. For example, BDNF has been shown to protect primary cortical neurons against methamphetamine-induced cell death [15] . A recent study demonstrated a change in BDNF mRNA levels from 1 h after repeated administration of a high dose (10 mg/kg) of methamphetamine in rats [16] .
Glial-derived neurotrophic factor (GDNF) is a member of a distinctly different family of neurotrophic factors. The common signalling receptor for all GDNF family ligands is the rearranged during transformation (RET) tyrosine kinase receptor [17] . GDNF activates several signalling cascades responsible for the regulation of cell survival, differentiation, proliferation, neurite outgrowth, and synaptic plasticity via the GDNF family receptor-α1 (GFR-α1) that can signal through RET [18] . Like BDNF, GDNF has been shown to protect rat dopaminergic neurons, e.g., against 6-hydroxydopamine toxicity [19] , and intracerebral GDNF administration has been shown to reduce the dopamine-depleting effects of neurotoxic doses of methamphetamine in rats [20] .
Neurotrophins can also influence functional synaptic plasticity [10, 21] . There is compelling evidence that BDNF can influence neuronal plasticity, and it has been implicated in the pathophysiology of many neuropsychiatric disorders [13] . BDNF has also been implicated in the behavioural sensitization and neuroadaptation to drugs of abuse in drug addiction [22] .
Taken together, this suggests that neurotrophins could play a role in the neuroplasticity that leads to addiction, and could also possibly moderate the neurotoxicity of methamphetamine if neurotrophin expression is stimulated. However, little is known about the acute effects of binge-like dosing regimens on neurotrophin levels. To further enhance the understanding of the neurotrophin response in the effects of methamphetamine, we investigated the acute effect of a dose range of low-to-moderate (0.5-4 mg/kg) binge-like methamphetamine treatments on the regional expression of neurotrophin proteins in the brain and serum 2 h after the last dose, in addition to assessing the behavioural effects and dopaminergic neurotransmitter changes produced.
Methods

Animals
Male Sprague-Dawley rats (body weight, 250-350 g) were used in this study. Procedures were carried out under the guidelines of the Animal Welfare Committee of the National University of Ireland, Galway, and in accordance with the EU Directive 2010/63/ EU. In the spirit of reduction, refinement and replacement, the numbers of animals per group were kept to a minimum. Rats ( n = 4-7 per time point) were housed singly and maintained on a 12-h light/dark cycle (lights on at 08: 00 and off at 20: 00). The housing facility was temperature (20 ° C ± 2 ° C) and humidity (40-60%) controlled. Food and water were available ad libitum.
Drugs Experimental Procedure
Rats received 4 subcutaneous (s.c.) doses (calculated as free base; 0.5, 1, 2, or 4 mg/kg, or saline for control) of (+)methamphetamine-HCl (purchased under license from Sigma-Aldrich, USA) 2 h apart. The animals were killed 2 h after the last dose ( n = 4-7 per group). The effects of methamphetamine on home cage locomotor activity was measured by the EthoVision ® video tracking system as described previously [23] . Briefly, the apparatus consists of 4 cameras suspended from the ceiling above 4 plastic-bottomed cages containing wood-shaving bedding, dyed with a black wood stain. Immediately following the first methamphetamine dosing, the animals were placed individually in their home cages. Their motor activity was then recorded for 4 h (preliminary study) or 8 h (main study; rats were dosed an additional 3 times, 2 h apart during the recording period). The images were analysed using the EthoVision software to derive the total distance moved over the duration. Body temperature was measured by rectal probe 2 h after the final methamphetamine dose, immediately following completion of the locomotor activity recording at the end of the experiment.
Upon completion of each experiment, the animals were killed by decapitation and each brain was dissected on ice into regions of interest bilaterally, i.e., the amygdala (and overlying cortical tissue), striatum, and frontal cortex, and then stored at -80 ° C until further processing. These brain regions were chosen on the basis of their involvement in cognitive behavior (frontal cortex), emotional behavior (amygdala), motor function (frontal cortex and striatum), and reward (striatum). Concentrations of dopamine, 1-3-4-dihydroxyphenylamine ( L -DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were measured by high-performance liquid chromatography (HPLC) with electrochemical detection as described previously [24] . In brief, bilateral brain tissue was weighed and sonicated in 1 mL of mobile phase (0. Brain regions were homogenized in lysis buffer on ice, and, following centrifugation at 4 ° C, the lysates were used for neurotrophin analysis. Duoset ® ELISA kits (R&D Systems, UK) were used to measure the concentration of BDNF and GDNF in duplicate brain tissue and serum samples, according to the manufacturer's instructions. Absorbance was read using an Anthos plate reader at 450 and 570 nm to correct for plastic interference. Total protein in brain tissue samples was assessed by Bradford assay (mg/mL). Neurotrophin concentration (pg/mg of protein) in brain tissue was recorded.
Statistical Analysis
Statistical comparisons were made by performing analysis of variance (one-way ANOVA with methamphetamine dose as the factor). Inter-group comparisons to control were assessed using the Dunnett multiple-comparisons post hoc test. The Tukey post hoc analysis was also employed to assess the significance of differences between different drug doses. All results were expressed as mean ± standard deviation (SD).
Results
Locomotor Activity
The repeat-dose regimen (4 doses administered 2 h apart) mimics binge drug-taking behaviour in humans, and it had a significant, dose-dependent effect on locomotor activity over the 8 h of observation (F 4, 14 = 29.47; p < 0.0001) ( Fig. 1 ) . Locomotor activity increased dose- Sprague-Dawley rats received methamphetamine 4 times 2 h apart, or saline (control). Results were analysed by one-way ANOVA followed by the Dunnett post hoc analysis. * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001, versus control.
dependently to a maximal level with the 2-mg/kg dose regimen. With the highest dose (4 mg/kg), locomotor activity was also significantly higher than the control, but lower than the peak locomotor activity. Although not quantified in this study, we observed the emergence of stereotyped rearing behaviour with the highest dose, which may have contributed to a decline in locomotor activity relative to the 2-mg/kg dose. As expected, methamphetamine caused hyperthermia. The body temperature of animals treated with the 4-mg/kg regimen of methamphetamine was 39.0 ± 0.3 ° C in comparison to 36.2 ± 0.5 ° C in controls.
Dopamine, L -DOPA, and Dopamine Metabolites
A significant increase in dopamine concentration was observed in the frontal cortex of animals treated with the highest dose of methamphetamine (4 mg/kg, 4 times, s.c.) (F 4, 18 = 6.80; p < 0.01) ( Fig. 2 ) . The increased dopamine concentration was dose-and region-specific, as no significant increase was observed in response to the lower doses of methamphetamine, nor was a significant change in dopamine levels observed in the amygdala (F 4, 21 = 1.48) or the striatum (F 4, 21 = 1.19).
L -DOPA levels had not changed in any brain region tested ( Table 1 ). There was also no change in either dopamine metabolite (DOPAC and HVA) in any brain region tested ( Table 1 ) 
Glial-Derived Neurotrophic Factor
One-way ANOVA and post hoc analysis showed no significant change in GDNF expression in the serum (F 4, 14 = 1.94) or amygdala (F 4, 14 = 0.32) following methamphetamine treatment ( Table 2 ) . There was an overall main effect of methamphetamine on GDNF expression in the frontal cortex (F 4, 21 = 2.96; p < 0.05), and the striatum (F 4, 14 = 3.91; p < 0.05), although the Dunnett post hoc analysis did not find an effect between controls and any specific dose. The Tukey post hoc analysis revealed a significant difference between the 0.5-mg/kg dose and the 4-mg/kg dose in the frontal cortex ( Table 2 ).
Brain-Derived Neurothrophic Factor
A significant reduction in BDNF levels in serum was observed following the methamphetamine repeated dosing (F 4, 14 = 3.07; p = 0.05). The post hoc analysis demonstrated that the highest concentration of methamphetamine significantly reduced serum BDNF levels in comparison to the control ( Fig. 3 ) .
A significant increase BDNF in the frontal cortex of animals treated with the highest dose (4 mg/kg) was observed (F 4, 18 = 16.54; p < 0.001) ( Fig. 4 ) . The increased BDNF concentration was dose-and region-specific, as no significant change was observed in response to the lower doses of methamphetamine. No significant change in BDNF was observed in the amygdala (F 4, 14 = 1.03) or striatum (F 4, 14 = 1.85).
It was of interest to investigate if there was a correlation between changes in dopamine and BDNF levels in the frontal cortex in response to methamphetamine treatment. The Pearson correlation coefficient analysis showed that there was a significant positive correlation between dopamine and BDNF levels in the frontal cortex with increasing doses of methamphetamine treatment ( r = 0.878; p = 0.025 [one-tailed analysis]). Biogenic amine levels (ng/g of fresh tissue) are expressed as mean ± SD. Results were analysed by one-way ANOVA followed by the Dunnett post hoc analysis. No significant change was observed. Results are expressed as mean ± SD and were analysed by one-way ANOVA, followed by the Dunnett post hoc analysis. * p < 0.05, versus control. Results are expressed as mean ± SD and were analysed by oneway ANOVA followed by the Dunnett and Tukey post hoc analyses. * p < 0.05, versus the 0.5-mg/kg dose regimen (Tukey post hoc test). 
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Discussion
The main findings in this paper relate to changes observed with the repeated administration of the highest dose (4 mg/kg) of methamphetamine, mimicking bingelike drug exposure in an addict. At this dose, but not at lower doses, methamphetamine increased the dopamine concentration and BDNF expression in the frontal cortex, and reduced the BDNF level in serum. The effect on dopamine and BDNF was brain region-specific and dosespecific.
Several groups of investigators have used either single or repeated doses of methamphetamine to investigate behavioural and biochemical changes in response to the drug in rats. The administration of single, large doses of up to 15 mg/kg s.c. have been reported [25] . However, repeated administration of lower doses is the more favoured approach as there is a reduced risk of mortality and also the dosing regimen more closely resembles typical binge drug-taking behaviour. In particular, a regimen using 4 injections of methamphetamine at 2-h intervals is a popular approach [16, [26] [27] [28] [29] . We identified the highest dose used in this study (4 mg/kg) as the highest safe level as higher doses increase mortality (data not shown). As expected, we observed a dose-dependent effect of methamphetamine on locomotor activity. Peak locomotion was observed with the 2-mg/kg regimen. We observed the emergence of rearing behaviour with the highest dose, which is in line with the literature [30] , and which may have contributed to the relative decline in locomotor activity from the peak with the 2-mg/kg dose. Stereotypy was not quantified in this study, but it would be of interest to fully quantify the stereotypy that develops following repeated methamphetamine administration in future work.
We were interested in the short-term effects on dopamine, assessed 2 h after binge-like methamphetamine treatment, and also how changes in neurotransmission might correlate with changes in neurotrophin expression. We found a significant positive correlation between the increase in dopamine and BDNF levels observed in the frontal cortex. The dopamine levels were significantly elevated 2 h after the last dose of methamphetamine, but only with the highest dose. Dopamine (D 1 ) receptor activation leads to an increase in cAMP, triggering intracellular cascades activating several kinases that phosphorylate CREB. Phosphorylation of CREB increases the transcription of many genes involved in cell survival and plasticity, including the BDNF gene [31] . It is highly likely that the increase in BDNF expression was directly related to the increased dopamine levels via this mechanism, as dopaminergic dysfunction profoundly influences BDNF expression in the frontal cortex [32] . Whilst our data suggests a direct relationship between high-dose methamphetamine treatment and the elevated levels of dopamine and BDNF in the frontal cortex, further work is required to examine the relationship more explicitly. It would be of interest to measure dopamine and BDNF release by microdialysis in freely moving animals. The effect of methamphetamine on dopamine release and BDNF levels in animals pretreated with D 1 and D 2 antagonists could also yield valuable insights into the mechanism of effect [33, 34] . The specificity of the increase in BDNF expression in the frontal cortex with the highest dose used in this study is a very interesting finding. We found an increase in BDNF expression in the frontal cortex 2 h after the last dose of methamphetamine, but only with the highest dose, and only in the frontal cortex. Our results concur with the work of Braun et al. [16] , who demonstrated that BDNF mRNA was increased in frontal, parietal, and ento-rhinal rat cortex following repeated dosing (4 times at 2-h intervals) of a higher dose of methamphetamine (10 mg/kg) at time points from 1 h after the last administration. It is possible that the raised mRNA levels 1 h after the last administration could have caused the increase in protein that we observed 2 h after the last dose, but further studies are required for confirmation. Our results provide evidence for the regional specificity of the rapid increase in BDNF protein expression, and also demonstrate the lower end of the dose regimen necessary to induce the increased expression of BDNF. Interestingly, an increase in BDNF mRNA has previously been reported in the frontal cortex in response to another amphetamine derivative, methylenedioxymethamphetamine (MDMA) [35] , and the psychostimulant cocaine has been shown to increase BDNF mRNA in the frontal cortex after administration [36] .
Methamphetamine has been shown to induce toxicity in vivo [27] and in vitro [37, 38] . There is evidence that BDNF may play a neuroprotective role against drug toxicity [39] . BDNF has been shown to suppress dopamine release and dopamine related-behaviour in methamphetamine-treated rats [40] . BDNF may also be involved in the neuroplasticity related to drug addiction [22] , and it has been suggested that increased brain BDNF may be a risk factor for drug addiction [41] . Alcohol has also been shown to increase BDNF expression in the rodent brain, and it has been suggested that this may reduce further alcohol consumption [42] . In the rat dorsolateral striatum, raised BDNF was shown to reduce alcohol intake whereas the down-regulation of BDNF using viral-mediated siRNA actually increased ethanol consumption [43] . BDNF was elevated within the mesolimbic dopamine system after cocaine withdrawal in rats, and it has been suggested that this can promote craving and relapse after prolonged abstinence from cocaine [44, 45] . It is possible that our observation of increased BDNF expression 2 h after the last binge-dose of methamphetamine may be related to a homeostatic neuroprotective feedback mechanism as well as to the neuroplasticity that underlies cravings and drug addiction, but further research is required in this area. We found no significant change in BDNF or dopaminergic neurotransmission in the striatum. In future work, it would be of interest to study the effect of methamphetamine on sub-regions of the striatum, specifically the caudate/putamen and nucleus accumbens, to separate out the effect of methamphetamine on the motor and reward functions of the striatum.
It has been suggested that elevated plasma BDNF in methamphetamine users may protect against neural damage [46] . Some studies have shown that plasma BDNF levels are increased in drug addicts [46] , and that serum levels decline with withdrawal [47] . However, other studies have shown that BDNF levels in the serum of methamphetamine addicts during withdrawal were lower than in controls [48] . Timing is a factor in these conflicting conclusions. The vast majority of circulating BDNF is stored in platelets [49] , which have a life span of about 10 days, so sampling over a protracted period could impact findings. Serum BDNF levels have been shown to be at least 10 times higher than plasma levels as platelets release BDNF from α-granules when activated, such as during blood clotting [50] . Animal studies investigating shortterm changes in BDNF expression caused by methamphetamine have primarily focused on the changes in brain regions, rather than in the serum. Here, we show that serum BDNF was reduced 2 h after binge-dosing with the highest concentration of methamphetamine, the same time point as when levels increased in the frontal cortex. A correlation between serum and cortical BDNF levels in rats was demonstrated previously [51] , although the time frame was in the order of weeks and months, not hours as in our study. The capacity of BDNF to cross the blood-brain barrier from the periphery has also previously been demonstrated [52] ; interestingly, within minutes of an intravenous injection, the labeled BDNF was detected in the parenchyma of the cerebral cortex. In our study, it is possible that platelet-derived BDNF crossed the blood-brain barrier in response to the methamphetamine treatment, and may thus have contributed to the increased BDNF levels in the frontal cortex 2 h after treatment. This is worthy of further study.
GDNF has also been proposed as a potential target to treat addiction [53] . The behavioural effects of drugs of abuse such as cocaine and alcohol are negatively regulated by GDNF [54] . GDNF infusion in the ventral tegmental area of rats decreased ethanol self-administration acutely and also in the long term [55] . GDNF may also be neuroprotective against the toxicity caused by drugs of abuse. It has been shown to attenuate the dopamine depletion promoted by methamphetamine when administered 1 day in advance [56] . In addition to GDNF, other members of the GDNF family, neurturin and artemin, when injected into the striatum 1 day before methamphetamine, were also found to protect the rat brain against methamphetamineinduced depletion of dopamine [20, 57] . We observed an overall main effect of methamphetamine on GDNF expression in the frontal cortex and striatum, but the post hoc analysis did not demonstrate significant differences from the effect in the controls. Due to the variability of samples, it would be useful to repeat this study with larger numbers to confirm the positive results, and also the negative findings observed (which commonly require larger numbers to confirm that no difference exists) [57] .
Conclusions
Collectively, these findings highlight the similar effects of methamphetamine on dopamine and BDNF, and also the importance of the frontal cortex brain region in methamphetamine-induced acute effects. Future work is needed to assess the longer-term effects of binge-like methamphetamine treatment on neurotrophin expression, particularly at dosages that cause neurotoxicity.
